Efficacy of targeted screening for familial hypercholesterolemia in children and adults aged <44 years: retrospective, prospective observational study
- 作者: Emelyanchik E.1, Moiseeva A.1,2, Emelyanchik V.1, Marilovtseva O.1,3, Khomchenkov R.3, Mosina V.1,3, Cherkashina I.1,4, Ustyugov S.1,3, Nikulina S.1,4, Protopopov A.1,3
-
隶属关系:
- Voino-Yasenetsky Krasnoyarsk State Medical University
- Krasnoyarsk Regional Clinical Center for Maternal and Child Health
- Krasnoyarsk Regional Hospital
- Berzon Krasnoyarsk Interregional Clinical Hospital No. 20
- 期: 卷 15, 编号 1 (2024)
- 页面: 19-30
- 栏目: Original study articles
- URL: https://journals.rcsi.science/2221-7185/article/view/256932
- DOI: https://doi.org/10.17816/CS623868
- ID: 256932
如何引用文章
全文:
详细
BACKGROUND: Considering the high cardiovascular risk in patients with familial hypercholesterolemia (FH), early diagnosis and treatment are the basis for the prevention of vascular accidents. In the absence of universal screening, the results of more targeted diagnostics are of interest — the search for lipid metabolism disorders in young relatives of patients with atherosclerotic vascular diseases.
OBJECTIVE: To determine the effectiveness of targeted screening for identifying patients with FH, which will justify its widespread use in clinical practice.
MATERIALS AND METHODS: At the start of the observational study, 584 patients were identified from the vascular centers of the Krasnoyarsk Regional Hospital, Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after. I.S. Berzon, who had lipid profile data and early cardiovascular events (all forms of coronary heart diseases), including reconstructive vascular interventions up to 55 years in men and up to 60 years in women in the case of first-degree relatives and up to 50 years in second-degree relatives. The study examined patients’ relatives aged <44 years. To diagnose FH in participants aged >16 years, the scale developed by a network of Dutch lipid clinics was used; in participants aged <16 years, the S. Broome criteria were used. Targeted screening and lipid parameters in individuals with probable, possible, and definite FH were analyzed. Data processing was performed using Microsoft Excel and Statistica v. 12.0 (USA). Parametric (calculation of the median and 25th and 75th quartiles) and nonparametric (statistical significance of differences was determined using the Mann–Whitney and χ2 tests) methods were used.
RESULTS: The study examined 70 children and 104 adults aged <44 years whose first- and/or second-degree relatives suffered premature vascular events. In the general group of participants, 42 (24.14%) patients had FH (of which 18 were <17 years old) and 37 (21.2%) had hyperlipoproteinemia (a). Definite FH was documented in 16 (9.1%) patients, probable in another 16, and possible in 9. Hyperlipoproteinemia (a) was found in 37 (21.2% of general group) patients, including 12 children (17.1% of pediatric group).
CONCLUSION: Not more than 30% of the population are aware of the hereditary nature of lipid metabolism disorders and atherosclerotic diseases. Targeted screening is the least expensive and most effective tool for identifying patients with FH and hyperdipoproteinemia (a).
作者简介
Elena Emelyanchik
Voino-Yasenetsky Krasnoyarsk State Medical University
编辑信件的主要联系方式.
Email: lenacor@mail.ru
ORCID iD: 0000-0001-5013-2480
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, KrasnoyarskAnastasia Moiseeva
Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Clinical Center for Maternal and Child Health
Email: anastasiyamarkovnamoiseeva.97@mail.ru
ORCID iD: 0009-0005-4002-6322
MD, graduate student
俄罗斯联邦, Krasnoyarsk; KrasnoyarskVasilii Emelyanchik
Voino-Yasenetsky Krasnoyarsk State Medical University
Email: vasogrow495@gmail.com
ORCID iD: 0000-0002-6447-0146
resident
俄罗斯联邦, KrasnoyarskOlga Marilovtseva
Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Hospital
Email: olguha83@mail.ru
ORCID iD: 0000-0002-1323-2367
MD, cardiologist
俄罗斯联邦, Krasnoyarsk; KrasnoyarskRoman Khomchenkov
Krasnoyarsk Regional Hospital
Email: homenko-007@mail.ru
ORCID iD: 0009-0000-5558-1912
MD, cardiologist
俄罗斯联邦, KrasnoyarskValentina Mosina
Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Hospital
Email: vamosina@mail.ru
ORCID iD: 0000-0002-7298-8965
MD, Cand. Sci. (Med.), associate professor
俄罗斯联邦, Krasnoyarsk; KrasnoyarskIrina Cherkashina
Voino-Yasenetsky Krasnoyarsk State Medical University; Berzon Krasnoyarsk Interregional Clinical Hospital No. 20
Email: cherkashina@list.ru
ORCID iD: 0000-0003-3825-3946
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, Krasnoyarsk; KrasnoyarskSergey Ustyugov
Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Hospital
Email: ustyugoff-s@yandex.ru
ORCID iD: 0000-0003-3105-1946
MD, Cand. Sci. (Med.), cardiologist
俄罗斯联邦, Krasnoyarsk; KrasnoyarskSvetlana Nikulina
Voino-Yasenetsky Krasnoyarsk State Medical University; Berzon Krasnoyarsk Interregional Clinical Hospital No. 20
Email: nicoulina@mail.ru
ORCID iD: 0000-0002-6968-7627
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, Krasnoyarsk; KrasnoyarskAlexey Protopopov
Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Hospital
Email: rector@krasgmu.ru
ORCID iD: 0000-0001-5387-6944
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, Krasnoyarsk; Krasnoyarsk参考
- Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. doi: 10.15829/1560-4071-2023-5471
- Mundal LJ, Igland J, Veierød MB, et al. Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia. Heart. 2018;104(19):1600–1607. doi: 10.1136/heartjnl-2017-312706
- Boytsov SA, Drapkina OM, Shlyakhto EV, et al. Epidemiology of cardiovascular diseases and their risk factors in regions of russian federation (esse-rf) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5): 143–152. doi: 10.15829/1728-8800-2021-3007
- Meshkov AN, Ershova AI, Shalnova SA, et al. Cross-sectional Study to Estimate the Prevalence of Familial Hypercholesterolemia in Selected Regions of the Russian Federation: Relevance, Design of the Study and Initial Characteristics of the Participants. Rational Pharmacotherapy in Cardiology. 2020;16(1):24–32. doi: 10.20996/1819-6446-2020-02-17
- Order of the Ministry of Health of Russia No. 404n of 27 April 2021. “On approval of the Procedure for conducting preventive medical examination and medical examination of certain groups of the adult population”. Available from: http://publication.pravo.gov.ru/Document/View/0001202106300043. Accessed: 16.03.2024. (In Russ).
- Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision. Moscow, 2020. Journal of Atherosclerosis and Dyslipidemias. 2020;1(38):7–42.
- Leontyeva IV. Modern strategy of diagnosis and treatment of children with heterozygous familial hypercholesterolemia. Rossiyskiy Vestnik Perinatologii i Pediatrii. 2020;65(4):27–40. doi: 10.21508/1027-4065-2020-65-4-27-40
- Matsunaga K, Mizobuchi A, Ying Fu YH, et al. Universal Screening for Familial Hypercholesterolemia in Children in Kagawa, Japan. J Atheroscler Thromb. 2022;29(6):839–849. doi: 10.5551/jat.62780
- Kusters DM, de Beaufort C, Widhalm K, et al. Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child. 2012;97(3):272–276. doi: 10.1136/archdischild-2011-300081
- Mainieri F, Tagi VM, Chiarelli F. Recent Advances on Familial Hypercholesterolemia in Children and Adolescents. Biomedicines. 2022;10(5):1043. doi: 10.3390/biomedicines10051043
- Leontyeva IV. Familial homozygous hypercholesterolemia in children: early diagnosis and treatment. Rossiyskiy Vestnik Perinatologii i Pediatrii. 2021;66(4):118–128. doi: 10.21508/1027-4065-2021-66-4-118-128
- Sadykova DI, Salakhova KR, Galimova LF, et al. Familial Hypercholesterolemia in Children. The Current State of the Problem. Current Pediatrics. 2023;22(3):231–240. doi: 10.15690/vsp.v22i3.2576
- Louter L, Defesche J, Roeters van Lennep J. Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler Suppl. 2017;(30):77–85. doi: 10.1016/j.atherosclerosissup.2017.05.019
- Hauguel-Moreau M, Aïdan V, Hergault H, et al. Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome. Arch Cardiovasc Dis. 2022;115(2):87–95. doi: 10.1016/j.acvd.2021.11.005
- Tada H, Okada H, Nomura A, et al. Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. J Clin Lipidol. 2021;15(2):358–365. doi: 10.1016/j.jacl.2020.12.012
- Chubykina UV, Ezhov MV, Afanas’eva OI, et al. Prevalence of familial hypercholesterolemia and hyperlipoproteinemia(a) in patients with premature acute coronary syndrome. Russian Journal of Cardiology. 2022;27(6):5041. doi: 10.15829/1560-4071-2022-5041
- Shakhtshneider EV, Ivanoshchuk DE, Makarenkova KV, et al. Cascade genetic screening in diagnostics of heterozygous familial hypercholesterolemia: clinical case. Russian Journal of Cardiology. 2017;(6):178–179. doi: 10.15829/1560-4071-2017-6-178-179
- Nordestgaard BG, Chapman MJ, Humphries SE, et al Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478a–3490a. doi: 10.1093/eurheartj/eht273. Erratum in: Eur Heart J. 2020;41(47):4517.
- Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ. 1991;303(6807):893–896. doi: 10.1136/bmj.303.6807.893
- Zueva IB, Baratashvili GG, Krivonosov DS. The role of lipoprotein (a) in the development of cardiovascular events and the therapeutic potential. Arterial'naya Gipertenziya. 2016;22(3):232–243. EDN: WXTEGP
- Langlois MR, Nordestgaard BG, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020;58(4):496–517. doi: 10.1515/cclm-2019-1253
- Lee C, Rivera-Valerio M, Bangash H, et al. New Case Detection by Cascade Testing in Familial Hypercholesterolemia: A Systematic Review of the Literature. Circ Genom Precis Med. 2019;12(11):e002723. doi: 10.1161/CIRCGEN.119.002723
补充文件
![](/img/style/loading.gif)